Drug to slow aortic stenosis shows early promise
Research we're watching
- Reviewed by Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
The drug, called ataciguat, works by binding to molecules that drive calcification within the valve. For the trial, 46 people with aortic stenosis were randomly assigned to receive ataciguat or a placebo for six months. Imaging tests revealed a reduction of nearly 70% in the progression of aortic valve calcification among those taking the drug compared to those on a placebo. People on the drug also showed improved heart function, including preserved pumping ability.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online Plus (HHO+) to unlock expert-backed health insights, personalized tools, and exclusive resources to feel your best every day.
Here’s what you get with your HHO+ membership:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
I’d like to subscribe to HHO+ for $4.99/month to access expert-backed content to help make smart, informed decisions about my well-being.
Sign Me UpAlready a member? Login ».
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
About the Reviewer
Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
